Glycopyrronium (PT001) vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Glycopyrronium (PT001)

Developed by AstraZeneca

Phase 2/3 in Asthmasmall molecule
Partial signal

NCT03358147 · Phase 2/3 · completed

The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.

Next expected readout: May 2029 · NCT07525375 (registry estimate)

Reported efficacy

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)

Result source: NCT03358147

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Phase 2 in Asthmasmall molecule
Partial signal

NCT01573624 · Phase 2 · completed

The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.

Reported efficacy

Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)

Result source: NCT01573624

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrronium (PT001)Umeclidinium
Severe exacerbations, annualised rate—Not reported—Trial running · NCT04651777
Trough FEV1, change0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
ACQ-5, change-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
—Trial running · NCT04651777
OCS dose reduction—Not reported—Trial running · NCT04651777

Severe exacerbations, annualised rate

Glycopyrronium (PT001)
—Not reported
Umeclidinium
—Trial running · NCT04651777

Trough FEV1, change

Glycopyrronium (PT001)
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
Umeclidinium
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539

ACQ-5, change

Glycopyrronium (PT001)
-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
Umeclidinium
—Trial running · NCT04651777

OCS dose reduction

Glycopyrronium (PT001)
—Not reported
Umeclidinium
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Glycopyrronium (PT001): 4 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrronium (PT001)Umeclidinium
Dropout rate
14.5%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
16.3%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
14.2%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
—100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
5.1%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
6.5%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
5.8%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
1.3%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
3.8%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.9%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
—100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
3.8%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
2.9%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0%100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
0%100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.6%100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.7%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.9%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
2.2%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
28.8 μg
upper respiratory tract infection 6% (placebo 8%)
nasopharyngitis 4.7% (placebo 3.4%)
sinusitis 4.3% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
14.4 μg
nasopharyngitis 6.3% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 2.9% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.2 μg
nasopharyngitis 7.1% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 1.7% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
100 mcg + 125 mcga
headache 2.3%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 18 more results
100 mcg + 15.6 mcg
headache 2.2%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 250 mcg
headache 3.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 31.25 mcg
headache 1.1%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 62.5 mcg
headache 2.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.25 mcg QD
nasopharyngitis 10.1% (placebo 11.9%)
headache 6.5% (placebo 7.7%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
62.5 mcg QD
nasopharyngitis 9.4% (placebo 11.9%)
headache 8.6% (placebo 7.7%)
upper respiratory tract infection 4.3% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrronium (PT001)

FEV1 AUC0-4 0.294 vs 0.24 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.284 vs 0.24 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.308 vs 0.24 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Moderate to Severe Exacerbation Rate Annualized 0.43 vs 0.55 placebo per year @ 24wk28.8 μg
event rate · per year
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.44 vs 0.55 placebo per year @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.41 vs 0.55 placebo per year @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-7 -0.78 vs -0.8 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.73 vs -0.8 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-0.9 vs -0.8 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-5 -0.87 vs -0.93 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.8 vs -0.93 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-1.02 vs -0.93 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
AQLQ 0.89 vs 0.96 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.9 vs 0.96 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
1.02 vs 0.96 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

Umeclidinium

FEV1 Trough 0.026 L @ 2wk100 mcg + 15.6 mcg
absolute change · L
No placebo or comparator arm
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
0.032 L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0385 L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0444 L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.051 L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Morning PEF 13 vs -2.9 FF L100 mcg + 15.6 mcg
absolute change · L
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
14.5 vs -2.9 FF L100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
15.7 vs -2.9 FF L100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
20 vs -2.9 FF L100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
19 vs -2.9 FF L100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Evening PEF 11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg
absolute change · L/min
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
16 vs -5.2 FF L/min100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
23.7 vs -5.2 FF L/min100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
17.7 vs -5.2 FF L/min100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Wm0 24 h 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.048 vs -0.025 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Evening PEF Change L/Min 1.5 vs -5.1 placebo L/min @ 2wk31.25 µg QD
absolute change · L/min
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
8.7 vs -5.1 placebo L/min @ 2wk31.25 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3 vs -5.1 placebo L/min @ 2wk250 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.8 vs -5.1 placebo L/min @ 2wk125 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
-0.9 vs -5.1 placebo L/min @ 2wk62.5 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
10 vs -5.1 placebo L/min @ 2wk15.6 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.5 vs -5.1 placebo L/min @ 2wk15.6 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
FEV1 Change 3 h 0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QD
absolute change · L
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
show 5 more results
0.052 vs 0.048 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.072 vs 0.048 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.093 vs 0.048 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.088 vs 0.048 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
Rescue Puffs -0.2 vs 0.6 FF Puffs @ 4wk100/250 µg
absolute change · Puffs
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
0 vs 0.6 FF Puffs @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Total -1.5 vs 0.5 FF score @ 4wk100/250 µg
absolute change · score
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Morning PEF 10.5 vs -14.2 FF L/min @ 4wk100/250 µg
absolute change · L/min
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
5.5 vs -14.2 FF L/min @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Umeclidinium's landscape